EGFR c.52C>A ;(p.L18I)

Variant ID: 7-55087022-C-A

NM_005228.3(EGFR):c.52C>A;(p.L18I)

This variant was identified in 9 publications

View GRCh38 version.




Publications:


PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.

Molecular Cancer
Kelm, Jeremy M JM; Pandey, Deepti S DS; Malin, Evan E; Kansou, Hussein H; Arora, Sahil S; Kumar, Raj R; Gavande, Navnath S NS
Publication Date: 2023-03-30

Variant appearance in text: EGFR: L18I
PubMed Link: 36991452
Variant Present in the following documents:
  • Main text
  • 12943_2022_Article_1707.pdf
View BVdb publication page



E3 ligase ligand optimization of Clinical PROTACs.

Frontiers In Chemistry
Jiang, Hanrui H; Xiong, Huan H; Gu, Shuang-Xi SX; Wang, Mingliang M
Publication Date: 2023

Variant appearance in text: EGFR: L18I
PubMed Link: 36733714
Variant Present in the following documents:
  • Main text
  • fchem-11-1098331.pdf
View BVdb publication page



Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.

Molecules (Basel, Switzerland)
Li, Rui R; Liu, Miao M; Yang, Zhenya Z; Li, Jiao J; Gao, Yuxin Y; Tan, Ruirong R
Publication Date: 2022-12-12

Variant appearance in text: EGFR: L18I
PubMed Link: 36557960
Variant Present in the following documents:
  • Main text
  • molecules-27-08828.pdf
View BVdb publication page



The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View.

Journal Of Experimental Pharmacology
Tambaro, Francesco Paolo FP; De Novellis, Danilo D; Wierda, William G WG
Publication Date: 2021

Variant appearance in text: EGFR: L18I
PubMed Link: 34744463
Variant Present in the following documents:
  • Main text
  • jep-13-923.pdf
View BVdb publication page



The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.

Hematological Oncology
Wang, Haoran H; Zhang, Wentao W; Yang, Jingyi J; Zhou, Keshu K
Publication Date: 2021-12

Variant appearance in text: EGFR: L18I
PubMed Link: 34651869
Variant Present in the following documents:
  • Main text
View BVdb publication page



Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.

Theranostics
Lin, Jiayi J; Jin, Jinmei J; Shen, Yiwen Y; Zhang, Lijun L; Gong, Gang G; Bian, Huiting H; Chen, Hongzhuan H; Nagle, Dale G DG; Wu, Ye Y; Zhang, Weidong W; Luan, Xin X
Publication Date: 2021

Variant appearance in text: EGFR: L18I
PubMed Link: 34373745
Variant Present in the following documents:
  • Main text
View BVdb publication page



Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation.

Frontiers In Cell And Developmental Biology
He, Ming M; Lv, Wenxing W; Rao, Yu Y
Publication Date: 2021

Variant appearance in text: EGFR: L18I
PubMed Link: 34249939
Variant Present in the following documents:
  • Main text
View BVdb publication page



Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.

Cancers
George, Bhawana B; Chowdhury, Sayan Mullick SM; Hart, Amber A; Sircar, Anuvrat A; Singh, Satish Kumar SK; Nath, Uttam Kumar UK; Mamgain, Mukesh M; Singhal, Naveen Kumar NK; Sehgal, Lalit L; Jain, Neeraj N
Publication Date: 2020-05-22

Variant appearance in text: EGFR: L18I
PubMed Link: 32455989
Variant Present in the following documents:
  • Main text
View BVdb publication page



Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.

Nature Communications
Kis, Olena O; Kaedbey, Rayan R; Chow, Signy S; Danesh, Arnavaz A; Dowar, Mark M; Li, Tiantian T; Li, Zhihua Z; Liu, Jessica J; Mansour, Mark M; Masih-Khan, Esther E; Zhang, Tong T; Bratman, Scott V SV; Oza, Amit M AM; Kamel-Reid, Suzanne S; Trudel, Suzanne S; Pugh, Trevor J TJ
Publication Date: 2017-05-11

Variant appearance in text: ERBB: 52C>A
PubMed Link: 28492226
Variant Present in the following documents:
  • ncomms15086-s3.xlsx, sheet 1
View BVdb publication page